INTRODUCTION
Left ventricular (LV) failure often occurs as a post-operative complication after lung transplantation in patients with pulmonary arterial hypertension (PAH) [9, 30, 130, 144] . It is associated with increased duration of intensive care stay and post-operative mortality [4, 67] . Recent studies suggest that LV dysfunction already occurs in early stages of PAH [35, 50, 92, 146] . LV dysfunction in PAH-patients is characterized by reduced ejection fraction (EF) and impaired diastolic function, and some studies reported a reduction in LV free wall mass in PAH-patients [35, 51, 92, 129] . However, the pathophysiology of LV dysfunction in PAH is incompletely understood.
Important determinants of LV function are cardiomyocyte cross-sectional area (CSA) and contractility. Recent data from PH rats show that LV cardiomyocyte CSA is reduced in end-stage disease [20, 48, 52] . However, it is unknown whether atrophy of LV cardiomyocytes also occurs in human PAH. The contractility of cardiomyocytes largely depends on the functioning of the contractile apparatus: the sarcomeres. The force generating capacity of sarcomeres is tightly regulated by post-translational modifications of sarcomeric proteins and by myosin-actin cross-bridge interactions. Whether sarcomere contractility is altered in LV cardiomyocytes of PAH-patients is currently unknown.
The aim of the present study was to investigate the CSA and contractility of LV cardiomyocytes isolated from biopsies of PAH-patients.
MATERIALS AND METHODS

Cardiac MRI
Retrospectively, 14 end-stage PAH-patients were selected based on cardiac MRI availability. Cardiac MRI was measured within 3 -17 months before transplant or death (median, 10 months). For comparison of right ventricular (RV) and LV volumes and mass, 15 controls were included, consisting of 5 patients suspected of PAH but in whom no cardiac cause was found and 10 healthy controls.
MRI was performed on a Siemens 1.5T Sonata or Avanto scanner (Siemens Medical Solutions, Erlangen, Germany). A stack of short-axis images covering the LV and RV was obtained according to our standard protocol [143] . During image post-processing using the MASS-software (MEDIS, Leiden, the Netherlands), a blinded observer assessed the ventricular masses and volumes by manually delineating the endocardial and-epicardial contours of the ventricles. Disk summation was performed according to Simpson's rule. Stroke volume (SV) was calculated as the difference between end-diastolic volume (EDV) and end-systolic volume (ESV). Ejection fraction was calculated as (SV/EDV) * 100%. The LV free wall mass was separated from the interventricular septum (IVS) by a line starting at the epicardial anterior and inferior RV-LV junctions ending at the LV endocardial wall. Masses and volumes were indexed to body surface area.
Left ventricular biopsies
Cardiac tissue from the LV free wall of 9 end-stage PAH-patients was collected during heart/lung transplantation. Non-failing cardiac LV tissue was obtained from 10 donor hearts. Samples were obtained after informed consent and with approval of the local ethical committee. All samples were immediately frozen and stored in liquid nitrogen. To determine CSA, 5 µm cryosections were cut and stained with a laminin antibody (1:200, L9393, Sigma-Aldrich, Zwijndrecht, the Netherlands). The CSA of at least 40 cardiomyocytes was determined per sample. Cardiomyocytes with non-transversal cross-sections were excluded from analysis [18, 20, 21, 115] . To correct for variation in sarcomere length between biopsy samples, perpendicular cryosections were cut and stained with anti α-actinin (1:40, A7811, Sigma Aldrich). CSA was normalized to a sarcomere length of 2.0 µm, assuming constant volume.
Left ventricular contractile function Experimental protocol
To study sarcomeric function, single LV cardiomyocytes of PAH-patients and donors were mechanically isolated and mounted in the experimental setup as described previously [70, 137, 138] . Briefly, cardiomyocytes were mechanically isolated and the cell membranes were permeabilized in relaxing solution containing 0.5% Triton X-100. A single cardiomyocyte was attached between a force transducer and a length motor, sarcomere length was set to 1.8, 2.0 or 2.2 µm.
The force generating capacity (F tot ) was determined by transferring the cardiomyocyte to activating solution (calcium concentration [Ca 2+ ] of 31.6 µM [29]). Force developed and when steady state was reached, the cardiomyocyte was rapidly shortened to 70% of its initial length, followed by a quick re-stretch to its original length [12, 121] . The rate of force redevelopment (k tr ) was determined by fitting a single exponential through the force redevelopment curve. Passive tension (F pas ) was determined by shortening the cell in relaxing solution to 70% of its original length. Active force was calculated by subtracting F pas from F tot . To determine tension, force was normalized to the CSA of the cardiomyocyte. 
Active stiffness
In a subset of cardiomyocytes active stiffness was determined. The cardiomyocyte was placed in activating solution ([Ca 2+ ] 31.6 µM), and when steady isometric tension was reached small length perturbations (1.4, 2.1, 2.8 % of initial length) were imposed on the cardiomyocyte resulting in a quick force response ( Fig. 2.1 ). The tension change ( T) was plotted as a function of the length change ( L). Active stiffness was derived from the slope of the fitted line and is an estimate of the number of cycling cross-bridges [15] . The ratio of maximal tension and active stiffness reflects the force generated per cross-bridge [15] .
Phosphorylation of sarcomeric proteins
To investigate post-translational modifications of the sarcomeric proteins, LV tissue of PAH-patients and donors was homogenized in RIPA buffer containing phosphatase and protease inhibitors (P5726, Sigma-Aldrich), 50 µg of protein extract was loaded on a 4-15% gradient polyacrylamide SDS-gel (Invitrogen, Carlsbad, CA) and 1D electrophoresis was performed. Subsequently, staining of the gel with ProQ Diamond in conjunction with SYPRO Ruby (Molecular Probes, Eugene, OR) reveals the content of phosphorylated (ProQ) and total sarcomeric protein (SYPRO) [70] . The phosphorylation levels of the sarcomeric proteins was expressed relative to SYPRO stained α-actinin.
To specifically analyze dephosphorylated cardiac Troponin I (TnI), proteins were separ-ated on 4-15% gradient polyacrylamide SDS gel and transferred to nitrocellulose paper. A polyclonal antibody directed against unphosphorylated cTnI (22b11, 1: 5000, Ab8290, Abcam, Cambridge, UK) was used. To correct for differences in protein loading, the level of unphosphorylated cTnI was normalized to actin stained with ponceau on the same blot.
To evaluate the abundance of the major contractile proteins, myosin and actin, in the LV samples, homogenates of PAH and donor LV tissue were run on a polyacrylamide gel and stained with SYPRO Ruby. Myosin heavy chain, from here on referred to as myosin, and actin bands were analyzed and the myosin/actin ratio was calculated.
Statistical analysis
Statistical analysis were performed using Graphpad Prism 5 for Windows (Graphpad Software Inc, San Diego, CA) and SPSS version 20 (SPSS Inc. Chicago, Illinois). Normal distribution was tested and if necessary logarithm transformation was performed. Cardiac MRI measurements, CSA, phosphorylation and protein content of the sarcomeric proteins were analyzed by independent Student t-test or Mann-Whitney U test for nonnormally distributed values. Two-way repeated measure ANOVA was used to analyze maximal tension, passive tension, active stiffness, force per cross-bridge and force-[
curves between donors and PAH-patients, with Bonferroni post-hoc tests. A p-value of < 0.05 was considered significant.
RESULTS
Cardiac MRI
Patients' characteristics, hemodynamics and MR results are shown in Table 2 .1. The right ventricle (RV) of PAH-patients was dilated and hypertrophied, which was accompanied by a decrease in RVEF. LVEF was significantly reduced in PAH-patients, and a trend (p=0.055) towards a lower LV end-diastolic volume was observed. Total LV mass index was increased in PAH-patients; however, after excluding the interventricular septum, LV free wall mass index was not significantly different between groups.
Atrophy of LV cardiomyocytes
An overview of the patients' demographics is shown in table 2.2. No statistical differences were observed between the donors and PAH-patients, with regard to age or sex. Cardiomyocyte CSA was determined in laminin stained LV cryosections (for typical example, see Fig. 2 .2A). LV cardiomyocyte CSA was significantly lower (∼30%) in PAH-patients ( Fig. 2.2B ). To evaluate contractile protein content, the myosin/actin ratio was determined. A significant reduction (∼30%) in the myosin/actin ratio was found in PAH-patients ( Fig. 2.2C ). Note that myosin/desmin ratio was reduced by 55% in PAH-patients, whereas actin/desmin ratio was only reduced by 25%. This indicates that LV cardiomyocytes are not only smaller, but also contain less myosin than donor cardiomyocytes do. 
Depressed contractility of LV cardiomyocytes Tension
The force generating capacity -normalized to CSA (i.e. tension) -was determined in permeabilized single LV cardiomyocytes of PAH-patients and donors. As in vivo cardiomyocytes operate at a range of sarcomere lengths, tension was determined at sarcomere lengths of 1.8, 2.0 and 2.2µm ( Fig. 2.3A ). LV cardiomyocytes of both PAH-patients and donors showed an increase in maximal tension with increasing sarcomere length, indicating preserved length-dependence of maximal force in PAH. However, across the whole range of sarcomere lengths, maximal tension was significantly lower (25% to 27%) in LV cardiomyocytes of PAH-patients (p interaction <0.05). This indicates that contractile strength of LV cardiomyocytes is severely reduced in PAH-patients.
Cross-bridge cycling kinetics
To evaluate the underlying cause of the reduced maximal tension, additional experiments were performed. The active force generated by sarcomeres in permeabilized single car- Maximal tension was significantly lower in PAH-patients ( ) than in donors ( ) at all sarcomere lengths. B. Cardiomyocyte active stiffness was significantly lower at a sarcomere length of 2.2µm in PAH-patients, indicating a reduction in the number of cycling cross-bridges during activation. C. The tension/stiffness ratio, a reflection of the force generated per cross-bridge, was not significantly different between groups at all sarcomere lengths. Data are presented as mean ± SEM, * p<0.05, * * p<0.01, * * * p<0.001 vs. donor. N indicates number of subjects studied.
diomyocytes is determined by: 1) the fraction of strongly bound cross-bridges; 2) the number of available cross-bridges; and 3) the force per cross-bridge [11, 37] . A reduction in maximal tension should be accompanied by a change in one or more of these three determinants.
The k tr provides information on the attachment and detachment rate of the cross- Fig. 2.1) . Active stiffness was significantly reduced in PAH-cardiomyocytes at a sarcomere length of 2.2µm (Fig. 2.3B ). This finding suggests that the number of available cross-bridges is reduced in PAH-cardiomyocytes, which is further supported by the observed reduction in myosin/actin ratio (Fig. 2.2C) . The tension/stiffness ratio, which reflects the force generated per cross-bridge, was not significantly different ( Fig. 2.3C ). Together, these results suggest that the reduced tension of LV cardiomyocytes in PAH-patients is predominantly caused by a reduction in the number of available cross-bridges.
Increased calcium sensitivity of force in LV cardiomyocytes
We also determined the Ca 2+ -sensitivity of force in LV cardiomyocytes by exposing them 
Hypophosphorylation of contractile proteins
To investigate potential molecular mechanisms that underlie the reduced tension and increased Ca 2+ -sensitivity of LV cardiomyocytes in PAH-patients, we assessed the phosphorylation status of sarcomeric proteins [70, 120] . Compared with donor LV tissue, overall phosphorylation of cardiac myosin binding protein C (cMyBPC) and cTnI was significantly lower in the PAH-patients (Fig. 2.5A ). A reduction of 44 ± 6 % ( Fig.  2 .5B) and 34 ± 6 % ( Fig. 2.5C ), respectively, for cMyBPC and cTnI, was found in PAH-patients. Phosphorylation of desmin and troponin T did not significantly differ between groups. By Western blot analyses, we confirmed the increase of unphosphorylated cTnI in PAH-patients compared with the donors. An antibody directed against unphosphorylated cTnI (22b11) showed a significant increase (219 ± 50 %) in unphosphorylated cTnI in PAH-patients (Fig. 2.5D ).
DISCUSSION
By combining cardiomyocyte mechanics with analyses of cardiomyocyte structure and protein composition we demonstrate that LV cardiomyocytes from PAH-patients have (for a schematic overview, see Fig. 2.6 ):
1. Smaller CSA, indicating atrophy 2. Reduced force generating capacity that persists after correction for atrophy, which is partly caused by loss of the major contractile protein myosin.
3. Reduced phosphorylation levels of key sarcomeric proteins, which may be responsible for the increased Ca 2+ -sensitivity of force.
We propose that these changes at the cardiomyocyte level contribute to the reduction of in vivo contractility of the LV in PAH-patients, as indicated by our observations with MRI 
LV CARDIOMYOCYTE DONOR LV CARDIOMYOCYTE PAH-PATIENT
Cardiomyocyte atrophy and weakness contribute to LV dysfunction in PAH
Several studies have reported on impaired LV function in PAH-patients [35, 50, 51, 92, 129] . LV dysfunction in PAH is closely related to changes in RV function, either via direct ventricular interaction, which in PAH-patients leads to limitations in LV diastolic filling by left-ward septum bowing, or via hemodynamic effects as a result of a decrease in RV output that causes reduced filling of the LV [35, 91, 92] . Thus far, the pathophysiology of LV dysfunction has not been completely understood. Using MRI, a reduced LV pump function in PAH-patients was observed, with no change in LV free wall mass. Some previous studies have demonstrated a higher total LV mass in PAH-patients, but they did not report the LV free wall mass separated from the interventricular septum [35] , whereas others have reported a significant reduction of LV free wall mass in PAH-patients [51] . Importantly, using biopsy material, we observed a marked reduction in the CSA of individual LV cardiomyocyte in PAH-patients, indicating that these cardiomyocytes are atrophied. The current study is the first to investigate the CSA of LV cardiomyocytes in PAH-patients. However, our clinical findings are supported by data from several studies in PAH-rats, which also reported a reduction of LV cardiomyocyte CSA [20, 48, 52] . The combination of reduced LV cardiomyocyte CSA with unaltered LV free wall mass suggests that extracellular changes (i.e. increased fibrosis or edema) may occur in the LV of PAH-patients. Indeed, previous work indicated increased collagen content and fibrosis in the LV of PAH-rats [20, 48, 74] .
The combined reduction in CSA and contractile function of cardiomyocytes leads to a substantial decrease in the pressure generating capacity of the LV. Together, these findings indicate that intrinsic alterations in cardiomyocytes impact LV systolic function in PAH-patients and contribute to the reduction in LVEF [35, 51, 92] and LV strain in these patients [50] .
In addition to systolic dysfunction, LV diastolic function and LV relaxation are impaired in PAH-patients [68, 129] . Interestingly, we did not observe a change in cardiomyocyte stiffness in PAH-patients. Therefore, we speculate that the increase in myofilament Ca 2+ -sensitivity in PAH-cardiomyocytes contributes to LV diastolic dysfunction in PAH, rather than changes in passive stiffness of LV cardiomyocytes. It should be noted that extra-sarcomeric changes, such as calcium handling by the sarcoplasmic reticulum (e.g. changes in sarcoplamsic/endoplasmic reticulum calcium ATPase expression, phospholamban phosphorylation) also contribute to LV diastolic dysfunction in PAH-patients [62] . Such changes could potentially affect both the contractility and the relaxation kinetics of the LV.
LV adaptations in PAH: caused by reduced filling?
In PAH-patients, LV filling is reduced due to impaired RV output and to septum bulging. We propose that reduced LV filling, and the concomitant reduced volume load of the LV, underlie the changes in LV cardiomyocytes in PAH-patients. Previous work showed that sustained reductions in cardiac load, induced by spaceflight or bed rest, lead to reductions in LV mass [25, 71, 108] and cardiomyocyte CSA [62] . These unloading-induced changes are similar to the changes observed in the LV cardiomyocytes of PAH-patients. Furthermore, in unloaded rat hearts, induced by heterotopic heart transplantation to the abdominal aorta, the contractile reserve, and Ca 2+ regulation of intact rat cardiomyocytes of unloaded hearts were depressed, suggesting cardiomyocyte contractile dysfunction [62] . Finally, unloading of the heart in rats has been shown to reduce phosphorylation levels of cTnI [120] , a finding that mimics the reduction in cTnI phosphorylation observed in LV cardiomyocytes of PAH-patients (Fig. 2.5 ).
Additional support for the notion that atrophy and weakness of LV cardiomyocytes are a consequence of LV unloading is provided by the comparison of LV cardiomyocytes with those of RV cardiomyocytes of the same PAH-patients. In contrast to LV cardiomyocytes, RV cardiomyocytes are overloaded as a result of the increased pulmonary vascular resistance. Hence, opposite findings in RV cardiomyocytes are expected if changes in loading explain the reduction in LV cardiomyocyte size and function. Recently, our group published findings on RV cardiomyocyte function in PAH-patients [115] . Importantly, the LV cardiomyocytes studied here are derived from mostly the same individuals from whom RV cardiomyocytes were studied. Indeed, opposite to the LV cardiomyocytes, we observed an increase in the force generating capacity and cardiomyocyte size in the RV of PAH-patients compared with donors. Furthermore, a 3-fold increase in RV cardiomyocyte stiffness was found in PAH-patients, whereas stiffness was not changed in LV cardiomyocytes from PAH-patients [115] . The opposing results from LV and RV cardiomyocytes from the same patients strongly support our proposition that unloading of the LV -rather than systemic effects associated with PAH -underlie the changes in contractile function of LV cardiomyocytes.
Study limitations
The group of PAH-patients consisted of patients with idiopathic PAH (iPAH; n=3) and congenital heart disease-associated PAH (CHD; n=6). It could be speculated that these different causes of PAH differentially affect LV function. Therefore, we also compared analyses of histology, contractility and phosphorylation between idiopathic PAH and congenital heart disease patients. Comparable results for CSA, maximal tension, EC 50 , myosin/actin ratio, cTnI phosphorylation, and cMyBPC phosphorylation of LV cardiomyocytes were found in idiopathic PAH and congenital heart disease patients (Fig. 2. 7 en 2.8), suggesting that the origin of PAH does not affect LV function in a different manner.
We aimed to increase our clinical understanding of the changes in the LV in PAH by studying in vivo LV function using MRI. As MRI data was not available from the PAH-patients from whom biopsy specimens were obtained, measurements were performed in a separate cohort of PAH-patients. Both PAH-groups consisted of patients with end-stage disease, undergoing a heart/lung transplant or awaiting heart/lung trans- plantation. Therefore, we argue that both groups are comparable and that the data can be translated. Control LV tissue was obtained from organ donors and, theoretically, high circulating catecholamine levels before organ harvest have affected phosphorylation levels in LV tissue from donors. However, phosphorylation of contractile proteins affects mostly the Ca 2+ -sensitivity of force in cardiomyocytes, with only minor or no effects on our key parameters: maximal active tension, passive tension, and cardiomyocyte CSA. It is, therefore, unlikely that differences between groups in these key parameters were caused by an altered phosphorylation status in donors. This notion is further supported when comparing these results with previous findings on the RV of the same PAH subjects [115] . Importantly, whereas both the LV and RV have been exposed to similar levels of systemic catecholamines, the changes in maximal and passive tension, and CSA in LV versus RV cardiomyocytes are in the opposite direction. This suggests that these changes are not caused by the phosphorylation status, but are driven by other factors Finally, it has been shown that cardiomyocyte contractility differs between various locations in the LV free wall [136] . The precise locations of the LV biopsies are unknown, but LV biopsies are routinely taken from random locations in the free wall of the LV. Furthermore, measurements were performed on random pieces of tissue isolated from the biopsies. Therefore, all biopsies and biopsy pieces together are likely to be representative for the LV as a whole.
Conclusions
The present findings provide new insights into the mechanisms underlying LV dysfunction in PAH. We demonstrate that LV cardiomyocytes of PAH-patients are not only atrophied, but also have a severely impaired contractility. We propose that contractile dysfunction of LV cardiomyocytes contributes to the post-operative complications observed in PAH-patients after a lung transplant, when the LV is suddenly re-exposed to higher filling pressures. Future therapeutic strategies aimed at targeting the contractile impairment and atrophy will reveal the clinical implication of LV dysfunction in PAH-patients.
